^
Association details:
Biomarker:NRAS G13D
Cancer:Mantle Cell Lymphoma
Drug:ASN007 (ERK2 inhibitor, ERK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors

Published date:
07/21/2021
Excerpt:
...ASN007 showed a strong tumor growth inhibition in MINO, a mantle cell lymphoma model with a NRASG13D mutation.
DOI:
10.1016/j.xcrm.2021.100350